恶性肿瘤患者凝血指标浓度变化特点分析

 目的 分析恶性肿瘤患者凝血指标浓度变化的特点。方法 115例肿瘤患者分为胃癌、肠癌和肺癌组，选择健康体检者50例为对照组。分别检测患者治疗前凝血指标的水平、化疗后随时间变化凝血指标的变化和对照组凝血指标进行对比。结果 肿瘤患者血浆凝血酶原时间(prothrombin time， PT)为(12.39±1.23)s，活化部分凝血活酶时间(activated partial thromboplastin time， APTT)为(30.58±7.43)s，纤维蛋白原(fibrinogen ，FIB)为(4.71±1.72)g/L，D-二聚体(D-Dimer)为(1.32±0.16)μg/ml水平明显高于对照组，差异有统计学意义(P<0.05);不同类型肿瘤患者血浆PT、APTT、FIB、D-Dimer水平均明显高于对照组，差异有统计学意义(P<0.05)。肺癌组血浆FIB水平明显高于肠癌组、胃癌组，差异有统计学意义(P<0.05)，而肠癌组血浆FIB水平与胃癌组比较无统计学意义。胃癌组、肺癌组和肠癌组血浆FIB水平在化疗不同时期均未见明显变化。结论 凝血指标对肿瘤的早期诊断、疗效监测有一定帮助，是肿瘤患者排除、预防静脉血栓的良好指标。

Clinical analysis of routine blood coagulation index concentration change in 115 cancer patients

Objective To study the characteristics of blood coagulation index concentration change in tumor patients. Methods 115 cancer pationts were divided into groups of stomach cancer, colon cance and lung cancer. For the patients, the levels of blood clotting index before and after chemotherapy coagulation index changes over time were detected and blood coagulation indexes were detected in 50 cases of control group. Results In patients with cancer, plasma prothrombin time (PT) (12.39±1.23)s, activated partial thromboplastin time (APTT) (30.58±7.43)s, fibrinogen (FIB) (4.71±1.72)g/L, D- dimer (D-Dimer) (1.32±0.16 )μg/ml levels were significantly higher than in the control group (P<0.05). In patients with different types of tumor plasma PT, APTT, FIB, D-Dimer levels were significantly higher than in the control group (P<0.05). In lung cancer group, plasma FIB level was significantly higher than in colorectal cancer group and gastric cancer group (P<0.05). The plasma FIB level in gastric cancer group and colorectal cancer group was not significantly different. In gastric cancer group, lung cancer group and colorectal cancer group, plasma FIB levels did not obviously change in different periods of chemotherapy. Conclusions Coagulation indices for tumor diagnosis and curative effect monitoring have some help and are good indicators to excluded tumor, and preven venous thrombosis.